The AHA today expressed support for and urged all senators to support an amendment to the Labor, Health and Human Services and Education appropriations bill that would help address the out-of-control cost of prescription drugs. Offered by Sens. Dick Durbin (D-IL) and Chuck Grassley (R-IA), amendment #3787 would provide funding to enable HHS to require disclosure of drug pricing information in direct-to-consumer advertising. “DTC advertising has the potential to lead to overutilization of high-cost prescription drugs, including when lower-cost but equally effective options may be available,” AHA wrote in a letter to senators. “This is contributing to the unsustainable rate of growth in prescription drug spending, which is consuming a bigger portion of health care dollars each year. Requiring disclosure of drug pricing information in DTC advertising will meaningfully enhance drug pricing transparency and provide useful information for consumers as they engage in discussions with their providers about the best treatment options for their individual health care needs.”

Related News Articles

Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…